Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle Spray Clear all
Completed Phase 3 Interventional Results available

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

NCT01656889
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
HP-802-247, Vehicle
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

NCT04490109
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis

NCT02025725
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis

NCT01947491
View directory record Official record
Conditions
Psoriasis
Interventions
DFD01 Spray, Comp01 Lotion, Vehicle Lotion, Vehicle Spray
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
40
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Encinitas, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

NCT01916226
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and Seasonal
Interventions
FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

NCT02618759
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DSXS, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers

NCT03233737
View directory record Official record
Conditions
No Disease State or Condition
Interventions
One spray CTY-5339-A, One spray CTY-5339-CB, One spray CTY-5339-P
Combination Product · Device
Lead sponsor
Cetylite Industries
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers

NCT02154087
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
HP802-247
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2016 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

NCT03488563
View directory record Official record
Conditions
Migraine
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
22
States / cities
Little Rock, Arkansas • Long Beach, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

NCT02998840
View directory record Official record
Conditions
Prehypertension, Hypertension, Stage I
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tustin, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Sep 3, 2026, 8:43 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

NCT06189638
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Antimicrobial Peptide PL-5 Topical Spray and Placebo
Drug
Lead sponsor
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Vista, California • Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Malaria: Relative Bioavailability and Food Effect of DSM265

NCT03637517
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DSM265-TPGS 34% SDD, 400 mg fasted, DSM265-TPGS 34% SDD, 400 mg fed, DSM265 25% SDD, 400 mg fasted
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

NCT00296491
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP), placebo nasal, ADVAIR DISKUS, placebo capsule, placebo DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
104
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
View directory record Official record
Conditions
Long Term Follow up Dry Eye Disease
Interventions
OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

NCT05082974
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Vance Thompson Vision ND
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

NCT03688802
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers

NCT02908620
View directory record Official record
Conditions
Anesthesia
Interventions
One spray CTY-5339-A, One spray CTY-5339-CB, Two sprays CTY-5339-A, One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)
Combination Product · Drug
Lead sponsor
Cetylite Industries
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT04036292
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

NCT05180500
View directory record Official record
Conditions
COVID-19, Pharmacokinetics, Safety
Interventions
Q-Griffithsin, Placebo
Drug
Lead sponsor
Sharon Hillier
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

NCT00794144
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Olopatadine Hydrochloride Nasal Spray 0.6%, Olopatadine Hydrochloride Nasal Spray Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Years to 5 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2010 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

NCT00763555
View directory record Official record
Conditions
Psoriasis
Interventions
CD 2027, Calcitriol Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Fridley, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

NCT01817790
View directory record Official record
Conditions
Allergic Rhinitis, Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
626 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

NCT03759197
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, Vehicle Spray
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults

NCT05114486
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine Ophthalmic administered with the Optejet dispenser, Placebo administered with the Optejet dispenser
Combination Product
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
40 Years to 55 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
San Diego, California • Fairfield, Connecticut • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 3, 2026, 8:43 AM EDT